Tacrolimus blood levels rise when the drug is broken down more slowly than expected, absorbed more quickly, or distributed differently through the body. Because tacrolimus has an extremely narrow therapeutic window, even modest shifts in metabolism or absorption can push trough concentrations into a toxic range. The most common culprits are drug interactions that block the liver enzymes responsible for clearing tacrolimus, but genetics, diet, infections, gut problems, and even your blood count can all play a role. Understanding these causes matters because high tacrolimus levels are not just a lab curiosity; they can damage the kidneys, nervous system, and other organs you are trying to protect.
How Tacrolimus Is Cleared From the Body
Almost all tacrolimus elimination depends on a family of liver and gut enzymes called CYP3A, primarily CYP3A5 and CYP3A4. Very little of the drug leaves the body unchanged. A second system, a transporter protein called P-glycoprotein (P-gp), acts as an efflux pump in the intestinal lining: it grabs tacrolimus molecules that have been absorbed and pushes up to half of them back into the gut before they ever reach the bloodstream.1PubMed Central. Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients – Section: Metabolism/Elimination Anything that slows CYP3A enzymes or blocks P-gp will reduce the body’s ability to clear tacrolimus, and blood levels climb as a result.
Prescription Drug Interactions
This is the single most frequent and most dangerous cause of unexpectedly high tacrolimus levels. Dozens of commonly prescribed medications inhibit CYP3A4, CYP3A5, or P-gp, and many transplant patients will need at least one of them at some point.
Azole Antifungal Drugs
Fungal infections are common after transplantation, and the antifungals used to treat them are among the strongest CYP3A4 inhibitors in clinical use. In kidney transplant patients given voriconazole or fluconazole alongside tacrolimus, plasma tacrolimus levels rose significantly, forcing clinicians to cut the tacrolimus dose.2PubMed Central. Effects of antifungal drugs on the plasma concentrations and dosage of tacrolimus in kidney transplant patients Itraconazole and ketoconazole carry the same risk.3PubMed Central. Drug-Drug Interactions Leading to Tacrolimus Toxicity in a Renal Transplant Patient With COVID-19: The Role of Paxlovid and the Mitigating Use of Phenytoin Azole antifungals are so routinely co-administered with tacrolimus in stem cell transplant settings that the interaction is well-documented, yet it still catches patients and prescribers off guard when doses are not adjusted.4PubMed. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation
Ritonavir and Paxlovid
The COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir) may be the most dramatic example of this problem. Ritonavir is an irreversible CYP3A4 inhibitor. It also blocks P-gp, so it shuts down both of the body’s main routes for removing tacrolimus. One case analysis estimated that co-administration increases the risk of tacrolimus toxicity roughly 57-fold.5PubMed Central. Paxlovid-Induced Tacrolimus Toxicity in the Treatment of COVID-19: A Case Report Because ritonavir’s inhibition is irreversible, tacrolimus levels can remain dangerously elevated for days after the last Paxlovid dose, until the body produces fresh enzyme. Significant dose reductions of tacrolimus are required if the two drugs must be used together.6Australian Prescriber. Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid)
Calcium Channel Blockers and Antibiotics
Diltiazem and verapamil, both commonly prescribed for blood pressure, can dramatically increase tacrolimus concentrations and trigger toxicity.7PubMed. Diltiazem increases tacrolimus concentrations The macrolide antibiotics clarithromycin and erythromycin carry similar risk.3PubMed Central. Drug-Drug Interactions Leading to Tacrolimus Toxicity in a Renal Transplant Patient With COVID-19: The Role of Paxlovid and the Mitigating Use of Phenytoin These are not obscure drugs. A transplant patient who sees a new doctor for a sinus infection or is started on a blood pressure medication by a cardiologist could easily end up on one without anyone cross-referencing the tacrolimus interaction. That is why transplant teams stress that every prescriber in a patient’s life needs to know they are on tacrolimus.
Genetics and Enzyme Activity
Not everyone breaks down tacrolimus at the same speed, and a large part of that variation is genetic. The gene CYP3A5 comes in different versions. People who carry the wild-type CYP3A5*1 allele produce a functional version of the enzyme and metabolize tacrolimus faster. Those who carry two copies of the CYP3A5*3 variant (called non-expressors) produce little to no CYP3A5 and clear tacrolimus much more slowly. The difference is substantial: non-expressors have roughly half the oral clearance of expressors, meaning the same dose produces much higher blood levels.8PubMed Central. CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
Studies in kidney transplant recipients confirm this pattern. In one cohort, tacrolimus concentrations in non-expressors were roughly double those of expressors on day one after transplant, even when doses were comparable.9American Journal of Transplantation. Outcomes of CYP3A5 Genotype Polymorphisms on Tacrolimus Concentrations in Renal Transplant Recipients Another study tracking patients over a full year found that concentrations remained consistently lower in expressors at every time point measured.10PubMed. Frequencies and Association of CYP3A5 Polymorphism With Tacrolimus Concentration Among Renal Transplant Recipients in Vietnam The frequency of these genetic variants differs by ethnicity: most people of European descent are CYP3A5 non-expressors, while a larger proportion of people of African and Asian descent carry the expressor genotype. Some transplant centers now use genetic testing before the first dose to guide initial dosing, but this is not yet universal.
A separate gene variant, POR*28, also influences how well the CYP3A enzymes function. A meta-analysis of 18 studies found that among CYP3A5 expressors, carriers of the common POR*1/*1 genotype had higher dose-adjusted tacrolimus concentrations than POR*28 carriers in the early days after transplantation.11PubMed Central. Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies In other words, multiple genes interact to determine how quickly you clear the drug.
Grapefruit and Other Dietary Factors
Grapefruit juice is perhaps the best-known food-drug interaction in medicine, and tacrolimus is squarely in the crosshairs. Grapefruit contains compounds called furanocoumarins, which inhibit CYP3A4 in the intestinal wall. They also block P-gp.12PubMed Central. Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food When you drink grapefruit juice and take tacrolimus by mouth, more of the drug survives the first pass through the gut lining and reaches the bloodstream, raising levels. The specific culprits are bergamottin and dihydroxybergamottin, which act as both reversible and mechanism-based inhibitors of CYP3A4.13PubMed Central. Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended‐Release Tacrolimus (LCPT) Using Grapefruit Juice The interaction can persist for hours after eating or drinking grapefruit, because some of these compounds destroy the enzyme permanently and the gut has to make new copies. Most transplant programs tell patients to avoid grapefruit entirely.
CBD and Herbal Supplements
Cannabidiol (CBD) products have become widely available, and transplant patients sometimes use them for pain, anxiety, or sleep without considering a possible interaction with tacrolimus. Lab studies show that CBD and its main metabolite inhibit tacrolimus breakdown significantly. In human liver microsomes, CBD reduced the rate of tacrolimus metabolism by about 44%, and the metabolite 7-OH CBD reduced it even more.14PubMed Central. Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro These are lab findings, not clinical trials, so the exact magnitude of the interaction in a living patient is still being worked out. But the direction is clear and the mechanism is the same CYP3A4 pathway implicated in other interactions. Herbal supplements like St. John’s wort are well-known to affect the same enzyme system, though in the opposite direction (it speeds metabolism rather than slowing it). The broader point for transplant patients is that “natural” does not mean “safe to combine with tacrolimus.”
Infection and Inflammation
This one surprises many patients and even some clinicians. When your body mounts an inflammatory response, whether from a COVID-19 infection, a bacterial illness, or another acute inflammatory event, pro-inflammatory cytokines can suppress the activity of CYP3A enzymes. The result is a phenomenon sometimes called phenoconversion: your genetic blueprint says you should metabolize tacrolimus at a certain rate, but inflammation temporarily reprograms your enzyme activity downward, and blood levels rise without any change in dose.
Researchers studying kidney transplant recipients with COVID-19 found that tacrolimus exposure increased during infection and attributed it to inflammation-driven downregulation of CYP3A metabolism.15PubMed Central. Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism Case reports have highlighted the same pattern in other acute illnesses: tacrolimus levels spike during the inflammatory phase and return to baseline as the infection resolves, with no drug interactions or adherence changes to explain the shift.16PubMed Central. Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation This is clinically important because transplant patients who get sick may need their tacrolimus doses reduced temporarily, and levels should be monitored closely until the illness passes.
Diarrhea and Gut Damage
Severe diarrhea, especially from infections like enterocolitis, can paradoxically raise tacrolimus levels. The logic is counterintuitive: you might expect diarrhea to flush the drug out faster, lowering levels. But tacrolimus absorption is heavily influenced by the intestinal lining cells that contain P-gp. When those cells are destroyed by inflammation or infection, the P-gp efflux pump disappears with them. Without P-gp pushing tacrolimus back into the gut lumen, more drug is absorbed into the bloodstream.17PubMed. Increased tacrolimus trough levels in association with severe diarrhea, a case report Transplant teams watch tacrolimus levels closely during any GI illness for exactly this reason.
Low Hematocrit and Blood Composition
Tacrolimus binds extensively to red blood cells. Routine monitoring measures the total drug concentration in whole blood, which includes both the drug bound to red cells and the small unbound fraction floating freely in plasma. Only the unbound fraction is pharmacologically active, meaning it is the portion that actually reaches tissues and produces effects, both therapeutic and toxic.
When your hematocrit drops (meaning you have fewer red blood cells, as often happens after surgery, during chemotherapy, or with anemia from any cause), there are fewer red cells for tacrolimus to bind to. More of the drug ends up in the unbound, active form. A patient can have a whole-blood trough level that looks perfectly normal while their unbound concentration is dangerously high.18PubMed Central. Case Report: Low Hematocrit Leading to Tacrolimus Toxicity Correcting for hematocrit significantly improves the accuracy of tacrolimus level predictions.19PubMed Central. Importance of hematocrit for a tacrolimus target concentration strategy In clinically unstable patients with fluctuating blood counts, some experts recommend aiming for the lower end of the therapeutic trough range to reduce the risk of toxicity from elevated unbound drug.20PubMed Central. Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation
Low albumin levels compound the issue. In early liver transplant recipients who become profoundly hypoalbuminemic, the unbound (active) concentration of tacrolimus can rise even further, since albumin normally binds some of the drug in plasma.21PubMed. Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation
Liver Dysfunction and Impaired Bile Flow
Because tacrolimus depends so heavily on CYP3A enzymes in the liver for clearance, any condition that damages liver function or reduces the liver’s metabolic capacity can slow elimination and raise blood levels. Elevated bilirubin, a marker of liver dysfunction or bile flow problems, has been associated with decreased biliary excretion of tacrolimus. In liver transplant patients, this creates a feedback loop: the transplanted liver is not yet functioning at full capacity, so it cannot clear tacrolimus efficiently, leading to higher drug exposure during the period when the organ is most vulnerable.22PubMed Central. Hemoglobin and total bilirubin may affect tacrolimus clearance in liver transplant patient following the early postoperative period: a case report
Formulation Mix-Ups
Tacrolimus comes in multiple oral formulations: immediate-release capsules (taken twice daily), extended-release capsules (once daily), and a separate once-daily extended-release tablet. These formulations are not interchangeable. They have different absorption profiles, and swapping one for another at the same milligram dose can produce very different blood levels. Medication errors involving substitution between tacrolimus formulations have been reported to cause adverse reactions, and prescribing information for the extended-release tablet explicitly warns against treating these products as equivalent.23Envarsus XR. Envarsus XR HCP Resources and Prescribing Information If you pick up your tacrolimus and the pills look different from what you normally take, confirm with your pharmacist before assuming it is a generic substitution.
Time of Day
Most transplant patients take tacrolimus in the morning and evening, but the body does not process the drug identically at both times. Research on kidney transplant recipients has found that tacrolimus exposure is lower after the nighttime dose compared to the morning dose, likely because CYP3A enzyme activity varies over a 24-hour cycle and appears to be higher at night.24PubMed Central. Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation The practical implication: if you shift the timing of your doses significantly, or skip a morning dose and double up at night, the resulting blood levels may not be what you expect. Consistency in timing helps keep levels stable.
Pregnancy
Pregnancy changes tacrolimus handling in ways that are easy to misread on a lab report. During pregnancy, whole-blood oral clearance of tacrolimus is about 39% higher than postpartum, so trough levels measured in whole blood tend to drop.25PubMed Central. Interpreting Tacrolimus Concentrations During Pregnancy and Postpartum Clinicians see those falling numbers and understandably raise the dose. The problem is that the unbound fraction of tacrolimus, the portion that is pharmacologically active, roughly doubles during pregnancy. So the dose increases that keep whole-blood trough concentrations in the target range can push unbound concentrations to much higher levels than intended. In other words, a pregnant transplant patient can have what looks like a well-managed tacrolimus level on paper while actually being exposed to a substantially higher active drug concentration. Specialized monitoring is critical during and after pregnancy.
What Toxicity Looks Like
When tacrolimus levels climb too high, the most common early warning is worsening kidney function, since tacrolimus is inherently nephrotoxic even at therapeutic levels. Tremor, headache, and elevated blood pressure often appear. In more severe cases, neurotoxicity can progress to confusion, seizures, or encephalopathy. One reported case involved a renal transplant patient who inadvertently overdosed on tacrolimus at home and developed altered mental status along with bilateral foot drop from nerve damage, confirmed on nerve conduction studies.26PubMed Central. Tacrolimus-induced encephalopathy and polyneuropathy in a renal transplant recipient The damage from sustained high levels can become permanent if not caught quickly, which is why routine trough monitoring exists and why patients are told to report new neurological symptoms immediately.
Why Age Alone Does Not Explain Much
You might expect older patients to clear tacrolimus more slowly given the general decline in liver function and enzyme activity with age. And in theory, age-related changes in CYP3A and P-gp expression should matter. But the evidence so far is surprisingly thin. Five population pharmacokinetic studies, spanning kidney, bone marrow, and liver transplant recipients, investigated age as a variable, and none found it to significantly affect tacrolimus bioavailability, distribution, or clearance.27PubMed. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly The likely explanation is that the enormous person-to-person variation in enzyme activity driven by genetics, medications, and illness overwhelms any age-related trend. Older patients are still at risk for high levels, but the risk comes from the same list of factors that affect younger patients, not from age alone.